Figure 6. Association of the gene signature with response to molecular targeted therapy in pancreatic ductal adenocarcinoma. (A) IC50 of BMS-536924, Erlotinib, Foretinib, Linsitinib, and Sabutoclax exhibited a distinct effect on the low- and the high-risk cohorts. (B) Quantitative analysis showed that BMS-536924, Foretinib, Linsitinib, and Sabutoclax were more sensitive in the low-risk cancer cells, whereas Erlotinib was more effective in the high-risk cancer cells.